Healthcare Services Committee

Honorary Chairperson: Ms. Aileen Nandi
Minister Counselor for Commercial Affairs
U.S. Embassy

 

Chairman: Mr. Madan R. Krishnan
Vice President and Managing Director
India Medtronic Pvt Ltd.

 

The Healthcare Services committee is focused on creating value for India’s healthcare delivery system through sustainable interactions with U.S. Embassy, Governments of India at the Centre and State. This is to catalyse increased engagements among healthcare stakeholders towards improved patient care outcomes and health for all. It aims for healthcare services that are safe, accessible, high quality, people-centred, and integrated are critical for moving towards universal health coverage. Service delivery systems are responsible for providing health services for patients, persons, families, communities and populations in general, and not only care for patients.

 

Healthcare services would also consider the whole spectrum of care from promotion and prevention to diagnostic, rehabilitation and palliative care, as well all levels of care including self-care, home care, community care, primary care, long-term care, hospital care, in order to provide integrated health services throughout the life course. The healthcare services and technology market are growing rapidly, which creates opportunities, risks, and structural questions for companies in the sector and those in the broader healthcare value chain.

 

 

Working Groups

 

1. Medical Technology

 

Chairperson: Ms. Meenakshi Nevatia
Managing Director
Stryker India Pvt. Ltd.

 

Secretariat: Mr. Shanky B. Xavier
Manager
Email: shanky.xavier@amchamindia.com

 

Sector Overview

 

Medical technology advances in the last few decades have not only changed the practice of medicine, but have also saved lives, increased access to care and improved quality of life. Life expectancy has boosted manifold across the world owing to advances in medical technology. Consistently, scientists made major advances in our understanding of the genetic code and transfer RNA and setting the stage for the exciting fields of genomics,
epigenomics and bioengineering.

 

No longer science fiction, AI and robotics are transforming healthcare. AI is getting increasingly sophisticated at doing what humans do, but more efficiently, more quickly and at a lower cost. The potential for both AI and robotics in healthcare is vast. Just like in our every-day lives, AI and robotics are increasingly a part of our healthcare eco-system. One of AI’s biggest potential benefits is to help people stay healthy so they don’t need a doctor, or at least not as often. The use of AI and the Internet of Medical Things (IoMT) in consumer health applications is already helping people. Technology applications and apps encourage healthier behaviour in individuals and help with the proactive management of a healthy lifestyle. It puts consumers in control of health and well-being.

 

AMCHAM has been working towards highlighting the critical role of the medical device industry in the healthcare scenario and working on the policy frame work with the government for creating and improving the ecosystem for medical devices in delivery of world class treatment, preventive medicare and diagnostics. The working group aims to foster partnership with government and trade bodies, and promote policies that ensure sustainable access to the latest, highest quality medical technologies by healthcare professionals and their patients in India.

 

2. Pharmacuticals

 

Chairman: Mr. Sarthak Ranade
Managing Director – Janssen India
Johnson & Johnson Pvt. Ltd.

 

Co-Chairperson: Ms. Jyotsna Ghoshal
Senior Director – Corporate Affairs
MSD Pharmaceuticals Pvt. Ltd.

 

Secretariat: Mr. Shanky B. Xavier
Manager
Email: shanky.xavier@amchamindia.com

 

Sector Overview

 

The pharma working group is keen to be an active partner with government, non-governmental organizations and other stakeholders in the area of healthcare with focus on improving the health and quality of life of Indian people by discovering, developing and making available safe, cost effective and quality medicines. The group also discusses the regulatory environment for the pharma industry in India.